ASMB
Assembly Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASMB
Assembly Biosciences, Inc.
A clinical-stage biotechnology company that develops therapeutics targeting hepatitis B virus and other viral diseases
Two Tower Place, 7th Floor, South San Francisco, California 94080
--
Assembly Biosciences, Inc., incorporated in Delaware on October 7, 2005, began operations in April 2007. The company is a biopharmaceutical company advancing clinical drug candidates that have the potential to improve the lives of millions of people living with chronic hepatitis B virus (HBV) worldwide, an early development program for highly recurrent genital herpes associated with herpes simplex virus (HSV-2) infection, a research program focused on the discovery of novel antiviral drugs for the treatment of destructive viral diseases, Including delta hepatitis virus (HDV) and transplantation-associated herpes virus.
Company Financials
EPS
ASMB has released its 2025 Q3 earnings. EPS was reported at -0.72, versus the expected -0.65, missing expectations. The chart below visualizes how ASMB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ASMB has released its 2025 Q3 earnings report, with revenue of 10.79M, reflecting a YoY change of 57.62%, and net profit of -9.20M, showing a YoY change of 4.34%. The Sankey diagram below clearly presents ASMB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
